A Phase II Study of Pembrolizumab, Letrozole, and Palbociclib in Patients with Metastatic Estrogen Receptor-Positive Breast Cancer

Conference Abstract
Written by Simran Padam

San Antonio Breast Cancer Symposium

View publication ↗

Simran Padam
Previous

Gut Microbiome Profiling of Patients with Metastatic Breast Cancer Undergoing Immune Checkpoint Inhibitor Therapy
Next

Barriers to Clinical Trial Enrollment of Older Adults with Cancer: A Qualitative Study of the Perceptions of Community and Academic Oncologists